Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
CCCC Stock Forecast 2026-2027
$3.58
Current Price
$420.16M
Market Cap
Buy 7
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to CCCC Price Targets
+738.0%
To High Target of $30.00
+207.3%
To Median Target of $11.00
+95.5%
To Low Target of $7.00
CCCC Price Momentum
-11.8%
1 Week Change
-8.7%
1 Month Change
+64.2%
1 Year Change
+87.4%
Year-to-Date Change
-30.8%
From 52W High of $5.17
+111.8%
From 52W Low of $1.69
📊 TOP ANALYST CALLS
Did CCCC Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if C4 Therapeutics is one of their latest high-conviction picks.
Latest CCCC Stock Price Targets & Analyst Predictions
Based on our analysis of 2 Wall Street analysts, CCCC has a bullish consensus with a median price target of $11.00 (ranging from $7.00 to $30.00). The overall analyst rating is Strong Buy (9.7/10). Currently trading at $3.58, the median forecast implies a 207.3% upside. This outlook is supported by 7 Buy, 0 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CCCC Analyst Ratings
7
Buy
0
Hold
0
Sell
CCCC Price Target Range
Low
$7.00
Average
$11.00
High
$30.00
Current: $3.58
Latest CCCC Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CCCC.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jun 1, 2026 | Evercore ISI Group | Gavin Clark-Gartner | Outperform | Maintains | $12.00 |
| Feb 27, 2026 | Barclays | Overweight | Maintains | $N/A | |
| Feb 23, 2026 | Brookline Capital | Buy | Maintains | $N/A | |
| Dec 17, 2025 | Barclays | Overweight | Maintains | $N/A | |
| Dec 2, 2025 | TD Cowen | Buy | Initiates | $N/A | |
| Sep 23, 2025 | Wells Fargo | Overweight | Maintains | $N/A | |
| Sep 23, 2025 | Barclays | Overweight | Maintains | $N/A | |
| Sep 22, 2025 | Stephens & Co. | Overweight | Reiterates | $N/A | |
| Sep 17, 2025 | Barclays | Overweight | Initiates | $N/A | |
| Sep 15, 2025 | Stephens & Co. | Overweight | Upgrade | $N/A | |
| Sep 4, 2025 | Guggenheim | Buy | Initiates | $N/A | |
| Dec 19, 2024 | Wells Fargo | Overweight | Upgrade | $N/A | |
| Nov 18, 2024 | Stephens & Co. | Equal-Weight | Initiates | $N/A | |
| Aug 6, 2024 | BMO Capital | Outperform | Reiterates | $N/A | |
| May 9, 2024 | Wells Fargo | Equal-Weight | Maintains | $N/A | |
| May 9, 2024 | Stifel | Buy | Maintains | $N/A | |
| Feb 26, 2024 | Morgan Stanley | Equal-Weight | Maintains | $N/A | |
| Feb 23, 2024 | Stifel | Buy | Reiterates | $N/A | |
| Jan 29, 2024 | JP Morgan | Neutral | Upgrade | $N/A | |
| Dec 13, 2023 | Stifel | Buy | Upgrade | $N/A |
C4 Therapeutics Inc. (CCCC) Competitors
The following stocks are similar to C4 Therapeutics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
CCCC
C4 Therapeutics
mkt cap
448.90M
C4 Therapeutics Inc. (CCCC) Financial Data
C4 Therapeutics Inc. has a market capitalization of $420.16M with a P/E ratio of -3.0x. The company generates $34.86M in trailing twelve-month revenue with a -297.8% profit margin.
Revenue growth is -15.0% quarter-over-quarter, while maintaining an operating margin of -451.6% and return on equity of -48.3%.
Valuation Metrics
Market Cap
$420.16M
Enterprise Value
$256.20M
P/E Ratio
-3.0x
PEG Ratio
0.1x
Price/Sales
12.4x
Growth & Margins
Revenue Growth (YoY)
-15.0%
Gross Margin
N/A
Operating Margin
-451.6%
Net Margin
-297.8%
EPS Growth
-15.0%
Financial Health
Cash/Price Ratio
+59.5%
Current Ratio
9.0x
Debt/Equity
25.0x
ROE
-48.3%
ROA
-19.9%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
C4 Therapeutics Inc. (CCCC) Business Model
About C4 Therapeutics Inc.
What They Do
Develops targeted protein degradation therapies.
Business Model
C4 Therapeutics Inc. operates as a clinical-stage biopharmaceutical company focused on creating innovative therapies that degrade proteins responsible for diseases. The company generates revenue by advancing its product candidates through clinical trials and establishing strategic partnerships with major pharmaceutical firms, which may involve licensing agreements, collaboration funding, and potential royalties on future sales.
Additional Information
The company is currently conducting Phase 1/2 clinical trials on its lead products targeting various cancers, including multiple myeloma and melanoma. With a strong pipeline and collaborations with industry leaders like Biogen and Roche, C4 Therapeutics is positioned to make significant advancements in oncology, potentially offering better treatment options with increased efficacy and safety compared to traditional therapies.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
104
CEO
Mr. Andrew J. Hirsch M.B.A.
Country
United States
IPO Year
2020
Website
www.c4therapeutics.comC4 Therapeutics Inc. (CCCC) Latest News & Analysis
Latest News
Quick Summary
C4 Therapeutics, Inc. (CCCC) and Illumina (ILMN) have shown performance metrics relative to their sector in 2023. Specific performance details were not provided in the excerpt.
Why It Matters
Performance comparisons provide insights into C4 Therapeutics and Illumina's market position, indicating potential investment opportunities or risks relative to their sector.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
C4 Therapeutics, Inc. (CCCC) is being evaluated for its potential as a top stock pick for momentum investors. Further analysis is needed to assess its viability.
Why It Matters
The mention of C4 Therapeutics as a potential top pick signals interest in its stock's upward momentum, which could attract investors seeking growth opportunities.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
C4 Therapeutics, Inc. (CCCC) is discussing advancements in multiple myeloma treatments, focusing on IKZF1/3 degraders, particularly the drug Cemsidomide.
Why It Matters
C4 Therapeutics' focus on innovative treatments for multiple myeloma, particularly IKZF1/3 degraders, may enhance its market position and drive stock performance, influencing investment decisions.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
C4 Therapeutics, Inc. (CCCC) and Clene Inc. (CLNN) performance data for the year has been compared to their sector, highlighting their relative standing. Further details on performance metrics were not provided.
Why It Matters
Performance comparisons highlight C4 Therapeutics and Clene's relative strength or weakness, influencing investor sentiment and potential stock price movements within their sector.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
Cemsidomide showed a 53% overall response rate at the 100 µg RP2D in Phase 2 trials, including complete responses and minimal residual disease-negative status.
Why It Matters
Cemsidomide's 53% response rate at RP2D signals strong efficacy in trials, potentially boosting its market value and attracting investment as a promising treatment option.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
C4 Therapeutics (CCCC) has been upgraded to Zacks Rank #2 (Buy), indicating improved earnings outlook, which could boost the stock in the near term.
Why It Matters
The Zacks Rank #2 upgrade signals strong earnings potential for C4 Therapeutics, likely boosting investor confidence and driving the stock price up in the short term.
Source: Zacks Investment Research
Market Sentiment:
Positive
Frequently Asked Questions About CCCC Stock
What is C4 Therapeutics Inc.'s (CCCC) stock forecast for 2027?
Based on our analysis of 2 Wall Street analysts, C4 Therapeutics Inc. (CCCC) has a median price target of $11.00. The highest price target is $30.00 and the lowest is $7.00.
Is CCCC stock a good investment in 2027?
According to current analyst ratings, CCCC has 7 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $3.58. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CCCC stock?
Wall Street analysts predict CCCC stock could reach $11.00 in the next 12 months. This represents a 207.3% increase from the current price of $3.58. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is C4 Therapeutics Inc.'s business model?
C4 Therapeutics Inc. operates as a clinical-stage biopharmaceutical company focused on creating innovative therapies that degrade proteins responsible for diseases. The company generates revenue by advancing its product candidates through clinical trials and establishing strategic partnerships with major pharmaceutical firms, which may involve licensing agreements, collaboration funding, and potential royalties on future sales.
What is the highest forecasted price for CCCC C4 Therapeutics Inc.?
The highest price target for CCCC is $30.00 from at , which represents a 738.0% increase from the current price of $3.58.
What is the lowest forecasted price for CCCC C4 Therapeutics Inc.?
The lowest price target for CCCC is $7.00 from at , which represents a 95.5% increase from the current price of $3.58.
What is the overall CCCC consensus from analysts for C4 Therapeutics Inc.?
The overall analyst consensus for CCCC is bullish. Out of 2 Wall Street analysts, 7 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $11.00.
How accurate are CCCC stock price projections?
Stock price projections, including those for C4 Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 17, 2026 2:16 AM UTC